Click here for our Support Forum                          Click to buy APS Gear!

We are NOT doctors.
 Our Medical Advisory team are currently in the process of writing the verbiage for this page, which will be directed towards medical doctors.

Currently, we have links to medical journal articles that may aid in treating a patient with APS.

*Page is still under Construction!*

eMedicine - Antiphospholipid Antibody Syndrome : Article by Barry L Myones, MD
Last Updated: October 26, 2004 Promtes an INR in the range of 2.5-3.5.  

eMedicine - Antiphospholipid Syndrome : Article by Steven Carsons, MD
Last Updated: December 5, 2004 Based on the most recent evidence, a reasonable target for the international normalized ratio (INR) is 2.6-3 for a minimum of 6 months for a first thrombosis. Patients with recurrent thrombotic events while well maintained on the above regimen may require an INR of 3-4 and generally receive anticoagulation therapy for life. For severe or refractory cases, a combination of warfarin and aspirin may be used.  

Listen to the Patient — Anticoagulation Is Critical in the Antiphospholipid (Hughes) Syndrome
© 2003. The Journal of Rheumatology Publishing Company Limited. Promotes an INR of greater than 3.0.  

Medical Progress- Antiphospholipid Antibody Syndrome
PDF File from the New England Journal of Medicine

Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes’) syndrome
Postgraduate Medical Journal 2003;79:81-83 © 2003 Fellowship of Postgraduate Medicine. Promotes an INR of greater than 3.0. (registration required)

Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants
Recommended therapeutic international normalized ratios (INRs) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event are controversial. Patients with lupus anticoagulants often have a prolonged prothrombin time, which may complicate management of anticoagulant therapy.  

Surgical Management of the Primary Dental Patient on Warfarin
Written to inform Dentists about treating Warfarin Patients  

Unusual Manifestations of the Antiphospholipid Syndrome
Reported by Ronald A. AshersonI MD,FACP,MD(Hon)FRCP,FCP(SA)FACR,and Ricard Cervera2 MD,PhD  

Warfarin in Antiphospholipid Syndrome — Time to Explore New Horizons
The Journal of Rheumatology Feb. 2005 Promotes an INR greater than 3.0.

Page updated on: 01/07/08

The APS Foundation of America, Inc. website and forums are independently funded and maintained by Heidi and Tina.

We comply with the HONcode standard for trustworthy health information: verify here.

Website created and maintained by Heidi P.

APSFA ©2005, 2006, 2007, 2008

APSFA Privacy Policy | APSFA Advertising Policy

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only.   If you think you may have a medical emergency, call your doctor or 911 immediately.